SG10201912401QA - Gene therapy for neuronal ceroid lipofuscinoses - Google Patents
Gene therapy for neuronal ceroid lipofuscinosesInfo
- Publication number
- SG10201912401QA SG10201912401QA SG10201912401QA SG10201912401QA SG10201912401QA SG 10201912401Q A SG10201912401Q A SG 10201912401QA SG 10201912401Q A SG10201912401Q A SG 10201912401QA SG 10201912401Q A SG10201912401Q A SG 10201912401QA SG 10201912401Q A SG10201912401Q A SG 10201912401QA
- Authority
- SG
- Singapore
- Prior art keywords
- gene therapy
- neuronal ceroid
- ceroid lipofuscinoses
- lipofuscinoses
- neuronal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504817P | 2017-05-11 | 2017-05-11 | |
| US201762599816P | 2017-12-18 | 2017-12-18 | |
| US201862652006P | 2018-04-03 | 2018-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912401QA true SG10201912401QA (en) | 2020-02-27 |
Family
ID=64105028
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910015S SG11201910015SA (en) | 2017-05-11 | 2018-05-11 | Gene therapy for neuronal ceroid lipofuscinoses |
| SG10201912401QA SG10201912401QA (en) | 2017-05-11 | 2018-05-11 | Gene therapy for neuronal ceroid lipofuscinoses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910015S SG11201910015SA (en) | 2017-05-11 | 2018-05-11 | Gene therapy for neuronal ceroid lipofuscinoses |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11591614B2 (en) |
| EP (1) | EP3621612A4 (en) |
| JP (2) | JP7273730B2 (en) |
| KR (1) | KR20200023280A (en) |
| BR (1) | BR112019023303A2 (en) |
| CA (1) | CA3061655A1 (en) |
| RU (1) | RU2019139555A (en) |
| SG (2) | SG11201910015SA (en) |
| WO (1) | WO2018209205A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017355502B2 (en) * | 2016-11-04 | 2023-08-31 | The Children's Hospital Of Philadelphia | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
| BR112020005249A2 (en) | 2017-09-22 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | gene therapy to treat mucopolysaccharidosis type ii |
| SG11202104295UA (en) * | 2018-11-14 | 2021-06-29 | Regenxbio Inc | Gene therapy for neuronal ceroid lipofuscinoses |
| AU2020271052A1 (en) * | 2019-04-08 | 2021-10-28 | The Children's Hospital Of Philadelphia | Treatment of lysosomal storage disease in the eye through administration of AAVs expressing TPP1 |
| BR112021020421A2 (en) * | 2019-04-12 | 2021-12-21 | Encoded Therapeutics Inc | Compositions and methods for administering therapeutic components |
| US20230304034A1 (en) | 2020-05-12 | 2023-09-28 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| BR112023015303A2 (en) | 2021-02-01 | 2023-11-14 | Regenxbio Inc | METHOD TO TREAT CLN2 DISEASE DUE TO TPP1 DEFICIENCY IN A SUBJECT |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| ES2563643T3 (en) | 1997-04-01 | 2016-03-15 | Illumina Cambridge Limited | Nucleic acid sequencing method |
| US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| ES2308989T3 (en) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | INCREASE IN THE EXPRESSION OF A NUCLEOTIDIC SEQUENCE HETEROLOGY FROM RECOMBINANT VIRECT VECTORS CONTAINING A SEQUENCE FORMING INTRACATENARY BASE PAIRS. |
| WO2001091803A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| CA2447240C (en) | 2001-05-18 | 2013-02-19 | Wisconsin Alumni Research Foundation | Method for the synthesis of dna sequences |
| ATE520707T1 (en) | 2001-11-13 | 2011-09-15 | Univ Pennsylvania | METHOD FOR THE DETECTION AND/OR IDENTIFICATION OF ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATION OF NEW SEQUENCES IDENTIFIED THEREFROM |
| EP2359869B1 (en) | 2001-12-17 | 2018-12-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| EP2434420A3 (en) | 2003-08-01 | 2012-07-25 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| EP2298926A1 (en) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| EP3409296A1 (en) | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
| WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
| CN104910025B (en) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | Alkamine lipid and its purposes |
| WO2010071832A1 (en) * | 2008-12-19 | 2010-06-24 | Nationwide Children's Hospital | Delivery of polynucleotides across the blood brain barrier using recombinant aav9 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| SG10201908848RA (en) | 2010-03-29 | 2019-10-30 | Univ Pennsylvania | Pharmacologically induced transgene ablation system |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US9249425B2 (en) | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
| KR102128248B1 (en) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Lipid nanoparticle compositions and methods for mrna delivery |
| EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Modified polynucleotides for the production of oncology-related proteins and peptides |
| DK2858677T3 (en) | 2012-06-08 | 2020-08-31 | Ethris Gmbh | PULMONARY DELIVERY OF MESSENGER RNA |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| ES2859605T3 (en) | 2013-07-26 | 2021-10-04 | Univ Iowa Res Found | Procedures and compositions for treating diseases of the brain |
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| ES2856090T3 (en) | 2014-09-24 | 2021-09-27 | Hope City | Adeno-associated virus vector variants for high-efficiency genomic editing and their methods |
| US20180236105A1 (en) | 2015-10-23 | 2018-08-23 | University Of Iowa Research Foundation | Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection |
| WO2017160360A2 (en) | 2015-12-11 | 2017-09-21 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav9 |
| AU2017215211C1 (en) | 2016-02-03 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| SG11201907714UA (en) | 2017-02-28 | 2019-09-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
-
2018
- 2018-05-11 JP JP2019562418A patent/JP7273730B2/en active Active
- 2018-05-11 SG SG11201910015S patent/SG11201910015SA/en unknown
- 2018-05-11 US US16/611,512 patent/US11591614B2/en active Active
- 2018-05-11 WO PCT/US2018/032278 patent/WO2018209205A1/en active Application Filing
- 2018-05-11 BR BR112019023303-2A patent/BR112019023303A2/en active Search and Examination
- 2018-05-11 CA CA3061655A patent/CA3061655A1/en active Pending
- 2018-05-11 KR KR1020197036041A patent/KR20200023280A/en not_active Application Discontinuation
- 2018-05-11 RU RU2019139555A patent/RU2019139555A/en unknown
- 2018-05-11 SG SG10201912401QA patent/SG10201912401QA/en unknown
- 2018-05-11 EP EP18798476.0A patent/EP3621612A4/en active Pending
-
2022
- 2022-12-29 US US18/148,077 patent/US20230383312A1/en active Pending
-
2023
- 2023-04-28 JP JP2023073941A patent/JP2023099113A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7273730B2 (en) | 2023-05-15 |
| US20200239908A1 (en) | 2020-07-30 |
| RU2019139555A (en) | 2021-06-11 |
| AU2018265531A1 (en) | 2019-11-14 |
| US20230383312A1 (en) | 2023-11-30 |
| JP2023099113A (en) | 2023-07-11 |
| US11591614B2 (en) | 2023-02-28 |
| SG11201910015SA (en) | 2019-11-28 |
| RU2019139555A3 (en) | 2021-10-12 |
| JP2020519292A (en) | 2020-07-02 |
| CA3061655A1 (en) | 2018-11-15 |
| BR112019023303A2 (en) | 2020-06-16 |
| KR20200023280A (en) | 2020-03-04 |
| EP3621612A4 (en) | 2021-06-16 |
| WO2018209205A1 (en) | 2018-11-15 |
| EP3621612A1 (en) | 2020-03-18 |
| WO2018209205A9 (en) | 2019-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282808A (en) | Gene therapy for neuronal ceroid lipofuscinoses | |
| SG10201912401QA (en) | Gene therapy for neuronal ceroid lipofuscinoses | |
| IL290149A (en) | Combination therapy for cancer treatment | |
| IL284577A (en) | Gene therapy | |
| EP3468594A4 (en) | Gene therapy of neuronal ceroid lipofuscinoses | |
| PL3389778T3 (en) | Device for photodynamic treatment | |
| HK1258319A1 (en) | Cancer therapy | |
| IL299099A (en) | Cancer treatment combinations | |
| HK1258518A1 (en) | Gene therapy for ocular disorders | |
| ZA201900052B (en) | Pharmaceutical combinations for treating cancer | |
| SI3612237T1 (en) | Gene therapy | |
| EP3546020C0 (en) | Cancer treatment apparatus | |
| HK1251794A1 (en) | Cancer treatment | |
| IL255564B (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| GB201707212D0 (en) | Gene therapy for ciliopathies | |
| GB201701968D0 (en) | Gene therapy | |
| IL275613A (en) | Gene therapy for eosinohilic disorders | |
| IL263085A (en) | Gene therapy | |
| GB201704634D0 (en) | Gene therapy | |
| GB201616821D0 (en) | Gene therapy | |
| GB201612105D0 (en) | Gene therapy | |
| GB201612104D0 (en) | Gene therapy | |
| EP3525114A4 (en) | Design verification apparatus | |
| GB201600559D0 (en) | Therapeutic molecules | |
| GB201601248D0 (en) | Cancer therapy |